Association of insulin resistance, insulin and leptin levels with coronary in-stent restenosis

AbstractBackgroundIn-stent restenosis remains the major limitation of coronary stent implantation. Leptin is a hormone strongly related to insulin resistance (IR). Moreover, insulin resistance and hyperinsulinemia are common in patients with coronary heart disease (CHD), each of the previous metabolic and hormonal factors might be involved in restenosis after stent implantation.ObjectiveThis study was planned to evaluate the relationship between insulin resistance, insulin, leptin levels and coronary in-stent restenosis after coronary stent implantation in non-diabetic patients with CHD and to determine their value in prediction of restenosis.Patients and methodsThe study included 48 non-diabetic CHD patients with previous successful coronary stent implantation. They were divided into two groups according to the presence of in-stent restenosis on follow-up coronary angiography (6–9months after stent implantation). The first group was CHD patients with in-stent restenosis which included 20 patients, the second group was CHD patients without restenosis which included 28 patients. All patients were subjected to complete clinical examination including determination of body mass index (BMI), waist to hip ratio (WHR) and laboratory investigations including fasting plasma glucose (FPG), fasting plasma insulin (FP insulin), lipid profile (total cholesterol, HDL-C, LDL-C, TG), glycoselated hemoglobin (HbA1c), plasma leptin, estimation of homeostasis model assessment of IR (HOMA-IR). All subjects were submitted to OGTT with estimation of 2-h post-prandial glucose (2-hPP glucose) and sum post-prandial insulin levels (sum PP insulin). Follow-up coronary angiography was done for all patients with the estimation of minimal luminal diameter (MLD), diameter stenosis % and late lumen loss.ResultsThere was highly significant increase in each of FP insulin, sum PP insulin, HOMA-IR, leptin, diameter stenosis % and late lumen loss (P<0.001) and a highly significant decrease of MLD (P<0.001) in CHD patients with in-stent restenosis when compared to CHD patients without in-stent restenosis. MLD is negatively correlated to each of FP insulin (r=−0.49, P<0.001), sum PP insulin (r=−0.60, P<0.001) HOMA-IR (r=−0.63, P<0.001) and leptin (r=−0.55, P<0.001) while late lumen loss was positively correlated to each of FP insulin (r=0.98, P<0.001), sum PP insulin (r=0.70, P<0.001), HOMA-IR (r=0.67, P<0.001) and leptin (r=0.72, P<0.001). Multiple regression analysis revealed that each of FP insulin, sum PP insulin, HOMA-IR and leptin can be considered an independent predictor of in-stent restenosis (P<0.001).ConclusionOur study revealed that insulin resistance, fasting and post-prandial hyperinsulinemia and hyperliptinemia are considered predictors of coronary in-stent restenosis. Evaluation of HOMA-IR, insulin levels after standard OGTT and leptin levels are important tools in an attempt to recognize subjects at risk of early restenosis among non-diabetic, CHD patients undergoing percutaneous coronary revascularization and stent implantation

KcMod: a crop coefficient model

This Program was written in July 2009 (by R.L. Snyder and A. Swelam), and revised in July 2010 and 2018 (by R.L. Snyder and E. Guerra). It aims to provide a practical tool for crop coefficient calculation according to local climate conditions, for both academic and non academic purposes. Part of the same study is published online and can be found at the following web pages: Crop Coefficients: A Literature Review Journal of Irrigation and Drainage EngineeringMarch 2016 Volume 142, Issue 3. Online publication date: December 23, 2015 https://ascelibrary.org/doi/abs/10.1061/%28ASCE%29IR.1943-4774.0000983 This publication includes the Kc data base and the Kc Report as supplemental material. Correcting Midseason Crop Coefficients for Climate Journal of Irrigation and Drainage EngineeringJune 2015 Volume 141, Issue 6. Online publication date: November 07, 2014 https://ascelibrary.org/doi/abs/10.1061/%28ASCE%29IR.1943-4774.0000839 The book about the entire PhD thesis is available on: https://www.scholars-press.com

Comparison of Egyptian and English Mediation Procedures in Construction

The mediation process is the parties\u27 will to the dispute to reach an amicable, non-binding settlement to end their dispute. The Egyptian legislature adopted the idea of issuing a draft law on mediation in civil and commercial matters to settle disputes between the parties, whether before the litigation stage or after appearing before the courts. The Egyptian Ministry of Justice held many community dialogue sessions to find the final version of the draft law. However, the concerned authorities have not issued the law until writing this paper. This research aims to compare and analyze the Egyptian mediation procedures and the British mediation procedures to improve, develop, and enhance the Egyptian ones especially the draft law as well as overcoming the obstacles that hinder the spread of mediation. On the one hand, presenting the Egyptian procedures in the draft mediation law and the rules of the Cairo Regional Center for International Commercial Arbitration, CRCICA. On the other hand, the British procedures represented in the Institute of Civil Engineers\u27 mediation rules, ICE

Comparison of Egyptian and English Mediation Procedures in Construction

The mediation process is the parties\u27 will to the dispute to reach an amicable, non-binding settlement to end their dispute. The Egyptian legislature adopted the idea of issuing a draft law on mediation in civil and commercial matters to settle disputes between the parties, whether before the litigation stage or after appearing before the courts. The Egyptian Ministry of Justice held many community dialogue sessions to find the final version of the draft law. However, the concerned authorities have not issued the law until writing this paper. This research aims to compare and analyze the Egyptian mediation procedures and the British mediation procedures to improve, develop, and enhance the Egyptian ones especially the draft law as well as overcoming the obstacles that hinder the spread of mediation. On the one hand, presenting the Egyptian procedures in the draft mediation law and the rules of the Cairo Regional Center for International Commercial Arbitration, CRCICA. On the other hand, the British procedures represented in the Institute of Civil Engineers\u27 mediation rules, ICE

Kinetic studies of adsorption of Fe(III) from aqueous solution by untreated and alkali-treated rice straw

Modifications of rice straws surfaces by sodium hydroxide (NaOH) were carried out in order to study the effects of this on the surface functional groups properties. Comparison was made between untreated and alkali-treated rice straws on the removal of Fe(III) from aqueous solution. In this study, four characterizations of raw rice straw have been conducted. The morphological characteristics by Scanning Electron Microscope (SEM), Energy Dispersive X-ray Analysis (EDXA)the functional group present in the rice straw by Fourier Transform Infrared (FTIR) spectroscopy and the X-ray Diffraction (XRD). The result of Scanning Electron Microscopy (SEM) also shows that rice straw is a porous material. Rice straw contains on –OH functional group that can bind with metal ions. To be able to enhance the sorption capacity of rice straw in metals, removing from waste water, alkali treatment should be done. This shows that rice straw can be used as adsorbent for ferric ions removing from wastewater.The effect of pH, sorption kinetics and isotherms were studied in batch experiments. The good correlation coefficient was obtained from pseudo second-order kinetic model, which agreed with conception as the rate-limiting mechanism. Sorption isotherm test showed that equilibrium sorption data were better represented by Temkin model. The highly efficient, low cost and the rapid uptake of Fe(III) by untreated (RS) in comparison with alkali-treated (MRS) rice straws, indicated that it could be an excellent alternative for the removal of ferric ions by sorption process

Encapsulated polycaprolactone with triazole derivatives and selenium nanoparticles as promising antiproliferative and anticancer agents

Background and purpose Polycaprolactone nanocapsules incorporated with triazole derivatives in the presence and absence of selenium nanoparticles were prepared and evaluated as antiproliferative and anticancer agents. Polycaprolactone nanoparticles were prepared using the emulsion technique. Experimental approach The prepared capsules were characterized using FT-IR, TEM and DLS measurements. The synthesized triazolopyrimidine derivative in the presence and absence of selenium nanoparticles encapsulated in polycaprolactone was tested for its in vitro antiproliferative efficiency towards human breast cancer cell line (MCF7) and murine fibroblast normal cell line (BALB/3T3) in comparison to doxorubicin as a standard anticancer drug. Key results The results indicated that encapsulated polycaprolactone with selenium nanoparticles (SeNPs) and triazole-SeNPs were the most potent samples against the tested breast cancer cell line (MCF7). On the other hand, all compounds showed weak or moderate activities towards the tested murine fibroblast normal cell line (BALB/3T3). Conclusion As the safety index (SI) was higher than 1.0, it expanded the way for newly synthesized compounds to express antiproliferative efficacy against tumour cells. Hence, these compounds may be considered promising ones. However, they should be examined through further in-vivo and pharmacokinetic studies

Carcinoma ex Pleomorphic Adenoma of the Salivary Glands: Distinct Clinicopathologic Features and Immunoprofiles Between Subgroups According to Cellular Differentiation

In carcinoma ex pleomorphic adenoma (CXPA), pleomorphic adenoma (PA) and diverse carcinoma components showing luminal (ductal) or non-luminal (myoepithelial) differentiation coexist. To elucidate the clinicopathological implications of cellular differentiation in CXPA and the potential role of p53, vascular endothelial growth factor (VEGF), c-erbB-2, c-kit, and glucose transporter 1 (Glut-1) in carcinogenesis, we analyzed 11 CXPAs with luminal differentiation (CXPAs-LD) and 6 CXPAs with non-luminal differentiation (CXPAs-NLD) and compared protein expressions in residual PAs and carcinomas by immunohistochemistry. Among the CXPAs-LD, 5 were invasive and 8 were histologically high-grade tumors. The 5-year survival rate was 72.7%. P53, c-erbB-2, VEGF, and Glut-1 were more immunoreactive in carcinoma components than in PAs (P = 0.008, 0.004, 0.002, and 0.024, respectively); c-erbB-2 overexpression was associated with high histological grade (P = 0.024). Carcinoma components frequently lacked c-kit expression (P = 0.009). CXPAs-NLD were all low-grade and invasive with a larger mean tumor size (5.2 cm) than CXPAs-LD (3.3 cm) (P = 0.040). The patients remained disease-free without significant immunohistochemical expression. The immunoprofiles and clinical course of CXPA differed according to cellular differentiation. Therefore, it is important to report the histological subtype and to assess potential biomarkers in diagnostic and therapeutic trials

Galectin-3C Inhibits Tumor Growth and Increases the Anticancer Activity of Bortezomib in a Murine Model of Human Multiple Myeloma

Galectin-3 is a human lectin involved in many cellular processes including differentiation, apoptosis, angiogenesis, neoplastic transformation, and metastasis. We evaluated galectin-3C, an N-terminally truncated form of galectin-3 that is thought to act as a dominant negative inhibitor, as a potential treatment for multiple myeloma (MM). Galectin-3 was expressed at varying levels by all 9 human MM cell lines tested. In vitro galectin-3C exhibited modest anti-proliferative effects on MM cells and inhibited chemotaxis and invasion of U266 MM cells induced by stromal cell-derived factor (SDF)-1α. Galectin-3C facilitated the anticancer activity of bortezomib, a proteasome inhibitor approved by the FDA for MM treatment. Galectin-3C and bortezomib also synergistically inhibited MM-induced angiogenesis activity in vitro. Delivery of galectin-3C intravenously via an osmotic pump in a subcutaneous U266 cell NOD/SCID mouse model of MM significantly inhibited tumor growth. The average tumor volume of bortezomib-treated animals was 19.6% and of galectin-3C treated animals was 13.5% of the average volume of the untreated controls at day 35. The maximal effect was obtained with the combination of galectin-3C with bortezomib that afforded a reduction of 94% in the mean tumor volume compared to the untreated controls at day 35. In conclusion, this is the first study to show that inhibition of galectin-3 is efficacious in a murine model of human MM. Our results demonstrated that galectin-3C alone was efficacious in a xenograft mouse model of human MM, and that it enhanced the anti-tumor activity of bortezomib in vitro and in vivo. These data provide the rationale for continued testing of galectin-3C towards initiation of clinical trials for treatment of MM